POP BIO announces $3M investment and JV formation with Eubiologics for the development of an RSV vaccine

POP Biotechnologies, Inc. (POP BIO), a preclinical stage biotechnology company developing next-generation drug and vaccines products, announces that it has entered an agreement to receive a multimillion dollar equity investment from South Korean vaccine manufacturer Eubiologics Co., Ltd. (Eubiologics) in conjunction with the establishment of a joint venture, EUPOP Life Sciences.

EUPOP Life Sciences (EPLS) intends to leverage POP BIO’s SNAP platform, which enables highly streamlined generation of highly immunogenic nanoparticle vaccines, with EuBiologics immune enhancing EuIMT technology for the development of a series of vaccine candidates directed at the prevention of respiratory syncytial virus (RSV), herpes zoster virus (Shingles), and Alzheimer’s disease.

RSV is the leading cause of lower respiratory tract illness (LRI) in infants and young children and is a significant cause of LRI in elderly and immunocompromised populations. In the U.S., RSV is the leading cause of hospitalization of infants, and globally, is second only to malaria as a cause of death in children under one year of age.

Presently, there are no vaccinations available for RSV and treatments options are limited. We are looking forward to working closely with Eubiologics and the EUPOP to build a vaccine pipeline that will leverage POP BIO’s next generation vaccine adjuvant. The companies believe that the combination of the novel platform technologies can generate a vaccine candidate that might save thousands of lives and help millions of patients worldwide each year.

About POP Biotechnologies, Inc.

POP Biotechnologies, Inc. is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The versatile PoP platform enables the creation of light-targeted drug delivery nanoparticles, currently under evaluation for the treatment of cutaneous metastatic breast cancer, and the SNAP vaccine platform, a platform for the creation of highly-immunogenic nanoparticle vaccines. The PoP technologies, exclusively licensed from the State University of New York Research Foundation (SUNY-RF), were developed by company founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo). POP Biotechnologies is currently a resident of the SUNY Buffalo incubator at Baird Research Park.

About POP BIO’s SNAP Technology

POP BIO’s Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of highly immunogenic particle-based vaccines through use of a cobalt modified variant of the PoP technology (CoPoP). The SNAP technology enables the stable particle-formation of virtually any recombinant antigen-bearing resulting in substantial improvements in the immune response with most antigens.